Feb. 6 at 5:14 PM
$NVO’s phase 3 miscalculation shook investor trust — shocking how far off the error went.
$PFE is running a similar story with Metsera hype (9.6 mg monthly) — likely tolerability issues ahead. This casts shadows even on smaller biotechs with better assets.
Some analysts aren’t helping either — remember the
$AMGN phase 2 hype predicting 28% weight loss from 8 pts with severe vomiting? 📉
Lesson: commercial success hinges on tolerability, not just dose or delivery route (see
$LLY tirzepatide).
Click to view @LatestInformation .to get the latest information.
